INTERVENTIONS FOR VALVULAR DISEASE AND HEART FAILURE
One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial
EuroIntervention 2018;14:877-883 published online July 2018. DOI: 10.4244/EIJ-D-18-00460
Patrick W. Serruys1*, MD, PhD; Rodrigo Modolo2, MD; Michael Reardon3, MD, PhD; Yosuke Miyazaki4, MD, PhD; Stephan Windecker5, MD, PhD; Jeffrey Popma6, MD, PhD; Yanping Chang7, MS; Neal S. Kleiman3, MD; Scott Lilly8, MD, PhD; Hafid Amrane9, MD, PhD; Piet W. Boonstra9, MD, PhD; Arie Pieter Kappetein7, MD, PhD; Yoshinobu Onuma4,10, MD, PhD; Lars Søndergaard11, MD, PhD; Nicolas van Mieghem4, MD, PhD
1. International Centre for Circulatory Health, NHLI, Imperial College London, London, United Kingdom; 2. Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 3. Houston Methodist DeBakey Heart and Vascul
Aims: The indication for transcatheter aortic valve implantation (TAVI) has evolved from inoperable patients to patients at increased surgical risk. In low-risk patients, surgical aortic
